Navigation Links
Rcadia's COR Analyzer Family of Products Receives Second FDA Clearance
Date:9/26/2007

HAIFA, Israel, Sept. 26 /PRNewswire/ -- Rcadia Medical Imaging, Ltd., developer of novel computer-aided diagnostic software, has received a second U.S. Federal Food and Drug Administration (FDA) clearance to market its COR Analyzer family of products, which assists in triaging patients for coronary artery disease (CAD). The new approval includes segmentation of the coronary tree with no human intervention and automatic detection of pathologies in the main coronary arteries.

Coronary artery disease is a major underlying cause for acute chest pain in Emergency Department (ED) patients. Annually, more than 5 million US patients present in the ED with acute chest pain. CT Angiography (CTA) is being rapidly adopted to triage patients in EDs across the U.S. Rcadia's COR Analyzer quickly identifies coronary artery disease and helps exclude patients without coronary arterial disease with a high negative predictive value (NPV). Rcadia's COR Analyzer system uses proprietary image processing algorithms allowing a no human intervention analysis of Coronary CTA studies to characterize patients. While improving ED workflow, it can lead to a more rapid diagnosis, enabling appropriate treatments and avoiding unnecessary delays and invasive tests in patients who do not have coronary artery disease.

"The COR Analyzer is expected to assist the ED staff in reading Coronary CTA studies 24/7. Prioritizing patients with CAD, identifying and characterizing pathologies will save time and improve workflow in the ED as well as the radiology and cardiology departments," commented Shai Levanon, Rcadia CEO.

Coronary CTA studies are sent from the CT scanner to the COR Analyzer and analyzed without human intervention. The COR Analyzer is highly reliable in ruling out coronary artery disease. In analyzing over 350 CTA studies, generated by all four CT manufacturers, the Rcadia COR Analyzer successfully identified coronary artery disease and had a high NPV of over 97%.

"As a result of the COR Analyzer high negative predictive value we are currently finalizing testing of the product and strongly hope to start using it to triage cases that need to be read, alerting the reader which patients are most likely to have coronary arterial disease. Since COR Analyzer automatically marks pathologies; this in turn will make reading cases significantly faster even for the experienced radiologists." added Nathan Peled, MD, Head Department of Radiology at the Lady Davis Carmel Medical Center in Haifa.


'/>"/>
SOURCE Rcadia Medical Imaging, Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Dade Behrings (hsCRP) Tests and BNTM Series Analyzers
2. Analyzers Offer Point-of-Care Lipid Panels
3. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
4. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
5. Urinalysis Analyzers: Large Capabilities in Every Size Device
6. New Study Confirms Role for Pertussis Immunization of Entire Family in Reducing Infant Pertussis
7. PromegaExpress Expands Easy Access to Products with New Cabinet
8. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
9. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
10. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
11. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... May 27, 2016 Amarantus BioScience Holdings, ... developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced ... presenting at two upcoming investor conferences: SeeThru Equity ... Avenue, New York City , NY ... Marcum MicroCap Conference   Where: Grand Hyatt Hotel, ...
(Date:5/26/2016)... , May 26, 2016   ... software and analytics, network solutions and technology-enabled ... announced it entered into a strategic channel ... of outpatient software solutions and revenue cycle ... specialty hospitals and rehabilitation clinics to optimize ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May ... QGEN ; Frankfurt Prime Standard: QIA) today announced that ... with Therawis Diagnostics GmbH to develop and commercialize predictive assays ... market PITX2 as a marker to predict effectiveness of anthracycline ... "We are pleased to partner with Therawis, which ...
Breaking Medicine Technology:
(Date:5/27/2016)... NY (PRWEB) , ... May 27, 2016 , ... With ... intervention to walk, the demand for a sustainable product to aid in the rehabilitation ... and aid in the recovery of individuals with hemiplegia due to stroke. , Ekso ...
(Date:5/27/2016)... ... May 27, 2016 , ... In response ... many who are unaware of the plight of aphasia. In collaboration with the ... “Stroke Awareness” campaign. , The link between stroke and aphasia is relatively unknown, ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees in ... come courtesy of leaders in the nursing and health care industry. It also provides ... associations—namely Abilene Christian University. , As the nursing industry is coming out of ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Despite last ... meeting, expect Janet Yellen and company to wait until March 2017 for an interest ... University’s J. Mack Robinson College of Business. , “The Federal Open Market Committee (FOMC) ...
(Date:5/26/2016)... ... 2016 , ... Cabot Corporation, Pfizer, and 3M are responsible ... documents and SEC filings. A jury has returned a verdict of $32.8 ... Case No. BC588866, Los Angeles County, California. The jury awarded $22.8 million in ...
Breaking Medicine News(10 mins):